Clinical Trials on Genes in France

Total 74 results

Assistance Publique - Hôpitaux de Paris

Completed

Administration of Methionine in Patients With Pulmonary Alveolar Proteinosis by Mutation of the MARS Gene. (MetPAP)

Pulmonary Alveolar Proteinosis | Mutation Ala393Thr of the MARS Gene | mutationSer567Leu of the MARS Gene

France
Federation Francophone de Cancerologie Digestive

Recruiting

Cohort of Tumors With POLE/D1 Mutation

Tumors | POLD1 Gene Mutation | POLE Exonuclease Domain Mutation

France
Centre Leon Berard

Recruiting

Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING) (TRacKING)

Cancer | Cancer Metastatic | ALK Fusion Protein Expression | FGFR2 Gene Translocation | FGFR3 Gene Translocation | NTRK Family Gene Mutation | Gene Fusion | ROS1 Gene Translocation | NTRK Gene Fusion Overexpression | ATIC-ALK Fusion Protein Expression | BCR-FGFR1 Fusion Protein Expression | COL1A1-PDGFB Fusion... and other conditions

France, Denmark, Netherlands, Austria, Germany, Italy, United Kingdom, Czechia, Poland, Slovenia, Spain
Institut Bergonié

Recruiting

Cancer Risk Assessment in Patients With a Constitutional Alteration of the PTEN Gene (COCO)

PTEN Gene Mutation

France
Pfizer

Terminated

Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

Locally Advanced or Metastatic Solid Tumors | Genes, BRCA 1

United States, Belgium, Spain, Denmark, Japan, France, Italy, Netherlands, United Kingdom
Assistance Publique Hopitaux De Marseille

Completed

Assessment of the Mutation of Pig-A Gene as Biomarker of Genotoxic Exposure in Humans (PIG-A)

Patient With Breast Cancer

France
Nantes University Hospital

Terminated

Analysis of Oculo-motor Deficiencies Associated With FMR1 Gene Expression (Genetic Abnormality Predisposing to a Neurodegenerative Disease)

Pre-mutation on FMR1 Gene

France
Sensorion

Recruiting

Natural History in Children up to 10 Years With Moderate to Profound Hearing Loss Due to Mutations in GJB2 / OTOF Genes (Otoconex)

Sensorineural Hearing Loss, Bilateral | Congenital Deafness | AUNB1 | DFNB1A | DFNB9 | OTOF Gene Mutation | GJB2 Gene Mutation

France
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7 | BRIP1 Gene Mutation | PALB2 Gene Mutation | ATM Gene Mutation | ATR Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | CHEK1 Gene Mutation | FANCA Gene... and other conditions

United States, Canada
Assistance Publique Hopitaux De Marseille

Unknown

Does Chemotherapy Train the Mutation of the Pig-A Gene? (PIGA)

Breast Cancer Female

France
University Hospital, Brest

Unknown

Evaluation of Pertuzumab-Trastuzumab and Taxane in the Standard Treatment of Metastatic Breast Cancer (EPTTCSM)

Breast Neoplasms | HER-2 Gene Amplification

France
Relay Therapeutics, Inc.

Active, not recruiting

REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

Cholangiocarcinoma | Intrahepatic Cholangiocarcinoma | FGFR2 Gene Mutation | FGFR2 Amplification | FGFR2 Gene Fusion/Rearrangement | FGFR2 Gene Translocation | FGFR2 Gene Activation | Other Solid Tumors, Adult

United States, France, Italy, United Kingdom, Korea, Republic of, Spain, Taiwan, Sweden, Germany, Netherlands, Singapore, Australia, Hong Kong
Centre Hospitalier Universitaire de Saint Etienne

Completed

Hyperekplexia in Patients With CTNNB1 Mutation (CTNNB1)

CTNNB1 Gene Mutation | Hyperekplexia

France
Pfizer
French College of General Hospital Pneumologists (CPHG)

Completed

Descriptive Observational Study ALK-2016-CPHG (ALK2016CPHG)

NSCLC | Crizotinib | ALK Gene Rearrangement or ROS1 Gene Rearrangement

France
Institut Claudius Regaud

Recruiting

Study of Families With an Hemopathies Predisposition Related to the DDX41 Gene. (LUCID)

DDX41 Gene Mutation

France
Taiho Oncology, Inc.

Terminated

TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations

Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations | Advanced or Metastatic Solid Tumors With Germline PTEN Inactivating Mutations

United States, United Kingdom, Austria, France
UNICANCER
ARCAGY/ GINECO GROUP; SOLTI Breast Cancer Research Group

Active, not recruiting

Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients. (DOLAF)

ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer | a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status

France
Pfizer
Medivation, Inc.; Myriad Genetic Laboratories, Inc.

Terminated

A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study) (ABRAZO)

Breast Neoplasms | BRCA 1 Gene Mutation | BRCA 2 Gene Mutation

United States, Spain, United Kingdom, Germany, France
Groupe Francophone des Myelodysplasies
Aprea Therapeutics

Unknown

Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine

Chronic Myelomonocytic Leukemia | Myeloproliferative Neoplasm | Acute Myeloid Leukemia With Gene Mutations | Myelodysplastic Syndrome With Gene Mutation

France
Sensorion

Not yet recruiting

A Phase I/II Clinical Trial With SENS-501 in Children Suffering From Severe to Profound Hearing Loss Due to Otoferlin (OTOF) Mutations (AUDIOGENE)

Otorhinolaryngologic Diseases | Ear Diseases | Hearing Disorders | Deafness | Hearing Loss, Sensorineural | Congenital Deafness | DFNB9 | OTOF Gene Mutation

France
Poitiers University Hospital

Active, not recruiting

Radiomics for prEdiction of lunG cAncer biologY

Non Small Cell Lung Cancer | Gene Mutation-Related Cancer | PD-L1 | PET/CT

France
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7 | FGFR1 Gene Amplification | FGFR2 Gene Amplification | FGFR2 Gene Mutation | FGFR3 Gene Mutation | FGFR1 Gene Mutation | FGFR3 Gene Amplification

United States, Canada
University Hospital, Grenoble

Completed

Development of the Tool " iPSC " for the Functional Study of Mutations Responsible for Mental Retardation (Rementips)

Healthy Volunteers | Intellectual Deficiency | Asymptomatic Carrier of the Mutation of the Gene MYT1L

France
Institut Claudius Regaud

Recruiting

Study for Characterisation of Predictive Parameters of Clonal Evolution in Subjects With GATA2 Germline Mutation (GATA-2)

GATA2 Gene Mutation

France
Centre Francois Baclesse
GFPC

Recruiting

A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies (GFPC 06-2018)

ALK Gene Rearrangement Positive | NSCLC Stage IV | NSCLC Stage IIIB | EGFR Gene Mutation | ROS1 Gene Mutation

France
Bayer

Completed

A Study Called EPI VITRAKVI to Compare Treatment Results in Patients With Infantile Fibrosarcoma (IFS), a Type of Connective Soft Tissue Cancer, Who Received a Treatment Called Larotrectinib From a Study Called SCOUT With Patient Data From an External Database (EPI VITRAKVI)

Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene Fusion | Infantile Fibrosarcoma

France
University Hospital, Montpellier
Hôpital Cochin; Hôpital Necker-Enfants Malades; Foch Hospital, Suresnes, FRANCE

Recruiting

Validation of Therapeutic Efficacy Targeting the Splicing Variants in Cystic Fibrosis and CFTR Pathologies (ONB-CFTR)

Cystic Fibrosis | CFTR Gene Mutation

France
Arog Pharmaceuticals, Inc.
Centre Leon Berard; Fox Chase Cancer Center

Unknown

Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST

GIST With D842V Mutated PDGFRA Gene

United States, France, Spain, Italy, Germany, Norway, Poland
Institut Curie

Recruiting

COsegregation of VARiants in Panel of Genes (COVAR)

Genetic Predisposition | Gene Mutation-Related Cancer

France, Guadeloupe, Martinique, Réunion
QED Therapeutics, Inc.
Helsinn Healthcare SA

Terminated

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

FGFR2 Gene Mutation | Advanced Cholangiocarcinoma

Korea, Republic of, United States, Belgium, Spain, Taiwan, China, United Kingdom, France, Canada, Germany, Thailand, Italy, Portugal, Australia, Puerto Rico
Taiho Oncology, Inc.

Active, not recruiting

Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements (FOENIX-CCA3)

Advanced Cholangiocarcinoma | FGFR2 Gene Rearrangements

United States, Spain, United Kingdom, Australia, Taiwan, Italy, France, Korea, Republic of, Belgium, Japan, Thailand, Germany, Brazil, Peru, Portugal, Argentina, Hong Kong, Mexico, Netherlands, Poland
Intergroupe Francophone de Cancerologie Thoracique

Completed

French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings

Carcinoma, Non-Small-Cell Lung | KRAS Gene Mutation | ALK Gene Mutation | BRAF Gene Mutation

France
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Eli Lilly and Company; Genentech, Inc.; Kazia... and other collaborators

Recruiting

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Brain | NTRK Family Gene Mutation | CDK Gene Mutation | PI3K Gene Mutation | ROS1 Gene Mutation | KRAS G12C Mutation

United States
UNICANCER

Completed

I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations (GETUG-AFU19)

KRAS Gene Mutation | Infiltrating Urothelial Carcinoma

France
xCures
Cancer Commons

Available

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

Melanoma | Head and Neck Cancer | Glioblastoma | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Small Bowel Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Cholangiocarcinoma | Bladder Cancer | Thyroid Cancer | ERK Mutation | MAPK Gene Mutation | KRAS Activating... and other conditions

United States
Hospices Civils de Lyon

Recruiting

Molecular, Pathologic Intra Tumoral Heterogeneity in Malignant Pleural Mesothelioma (SCITH-MESO)

Mesothelioma, Malignant | Pleural Mesothelioma | Gene Abnormality

France
University Medical Center Groningen
Radboud University Medical Center; Maastricht University Medical Center; Erasmus... and other collaborators

Recruiting

Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels (ADAPT ALEC)

Carcinoma, Non-Small-Cell Lung | Lung Cancer | Drug Monitoring | Anaplastic Lymphoma Kinase Gene Mutation | Anaplastic Lymphoma Kinase Gene Translocation

Netherlands, France
Bayer

Recruiting

Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body (ON-TRK)

Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion

United States, Austria, Denmark, Germany, Italy, Norway, Spain, United Kingdom, Brazil, Russian Federation, Switzerland, Taiwan, Canada, China, Australia, Greece, Belgium, Sweden, Korea, Republic of, France, Argentina, Finland, Ireland and more
Pfizer
Medivation, Inc.

Completed

A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) (EMBRACA)

Breast Neoplasms | BRCA 1 Gene Mutation | BRCA 2 Gene Mutation

Korea, Republic of, United States, Australia, Spain, Belgium, France, Ireland, Taiwan, Poland, Germany, Israel, Brazil, United Kingdom, Italy, Russian Federation, Ukraine
AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetic Laboratories, Inc.

Active, not recruiting

Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (OlympiAD)

Breast Cancer Metastatic | BRCA 1 Gene Mutation | BRCA 2 Gene Mutation

Italy, Spain, United States, Czechia, Romania, France, Korea, Republic of, United Kingdom, Hungary, Japan, Peru, Poland, Russian Federation, Turkey, China, Taiwan, Bulgaria, Switzerland, Mexico
Day One Biopharmaceuticals, Inc.

Recruiting

Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors

Melanoma | Colorectal Cancer | Solid Tumor | Non Small Cell Lung Cancer | Bladder Cancer | Thyroid Cancer, Papillary | Pilocytic Astrocytoma | Bladder Urothelial Carcinoma | Non-Small Cell Adenocarcinoma | MEK Mutation | RAS Mutation | Pancreatic Acinar Carcinoma | RAF Mutation | CRAF Gene Amplification | RAF1 Gene Amplification and other conditions

United States, Canada, Korea, Republic of, Spain, Australia, Belgium, France
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

CCND1 Gene Amplification | CCND2 Gene Amplification | CCND3 Gene Amplification | CDK4 Gene Amplification | Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7

United States
Intergroupe Francophone de Cancerologie Thoracique
Pfizer

Completed

Efficacy of Treatment Sequences in Patients With Non-small Cell Lung Cancer Receiving Lorlatinib (LORLATU)

ALK Gene Rearrangement Positive | Non-small Cell Lung Cancer Metastatic | ROS-1 Gene Rearrangement Positive

France
Hutchmed

Recruiting

A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH

Isocitrate Dehydrogenase Gene Mutation

Spain, United States
Calithera Biosciences, Inc

Terminated

KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC (KEAPSAKE)

Non-Small Cell Lung Cancer | Non-squamous Non-small-cell Lung Cancer | Non-Squamous Non-Small Cell Neoplasm of Lung | KEAP1 Gene Mutation | NRF2 Gene Mutation | NFE2L2 Gene Mutation

United States
Hospices Civils de Lyon

Recruiting

Characterization of a Functional Test for Mediterranean Family Fever Screening - 2 (DEPIST-FMF 2)

Familial Mediterranean Fever | MEFV Gene Mutation

France
Assistance Publique - Hôpitaux de Paris
Centre Leon Berard; Institut National de la Santé Et de la Recherche Médicale... and other collaborators

Not yet recruiting

Impact of Environmental Exposures on Tumor Risk in SDHx-mutation Carriers (PGLEXPO2)

Environmental Exposure | SDH Gene Mutation | SDH-Related Familial Paraganglioma | SDHx-Related Syndromes

France
Turning Point Therapeutics, Inc.

Active, not recruiting

Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET (SHIELD-1)

Advanced Solid Tumor | Metastatic Solid Tumors | MET Gene Alterations

United States, France, Korea, Democratic People's Republic of, Korea, Republic of, Spain
Intergroupe Francophone de Cancerologie Thoracique

Completed

Her2-positive Lung Cancer Treated With Dedicated Drug (R2D2)

Non Small Cell Lung Cancer Metastatic | HER2 Gene Mutation | Non Small Cell Lung Cancer Stage III

France
Centre Leon Berard

Completed

Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (ImadGist)

Gastrointestinal Stromal Tumors | Resected Gastrointestinal Stromal Tumors | Non-metastatic | High Risk of Recurrence | KIT Gene Mutation

France

Clinical Trials on Genes in France

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations